Introduction {#S0001}
============

The increasing resistance of *Staphylococcus aureus* to antibiotics is a serious challenge for clinicians. Methicillin-resistant *S. aureus* (MRSA) is defined as *S. aureus* with a minimum inhibitory concentration (MIC) to oxacillin of ≥4 µg/mL, as opposed to methicillin-sensitive *S. aureus* (MSSA), which is sensitive to penicillins and cephalosporins.[@CIT0001] In addition to β-lactam antibiotics, MRSA also shows resistance to macrolides, aminoglycosides, and fluoroquinolones.[@CIT0002] The multidrug resistance often encountered in MRSA strains greatly limits the treatment options.[@CIT0002] An environment with high antibiotic selection pressure (like hospitals) is conducive to the development and propagation of MRSA,[@CIT0002] and the reported incidence of hospital-acquired MRSA ranges from 11.5% to 60%.[@CIT0003]--[@CIT0005] MRSA is associated with significant morbidity, mortality, increased length of stay, and higher costs.[@CIT0001] Continuous surveillance of drug resistance helps improve the management of patients with infection and provide guidance for the optimal selection of effective antimicrobial agents.[@CIT0006]

Ceftaroline is a fifth-generation broad-spectrum cephalosporin, and it is active against MRSA and Gram-positive bacteria, and, to a lesser extent, against Gram-negative bacteria.[@CIT0007] It is used for community-acquired pneumonia and complicated skin infections.[@CIT0008]--[@CIT0011] Against MRSA, it is reported to be non-inferior to vancomycin.[@CIT0012]--[@CIT0014]

The patterns of ceftaroline resistance against MRSA around the globe still remain to be defined exactly. This study aimed to investigate the susceptibility of *S. aureus* to ceftaroline and comparator antimicrobial agents in patients hospitalized due to infection and to observe the variation among different regions and years.

Materials And Methods {#S0002}
=====================

Bacterial Isolates {#S0002-S2001}
------------------

The Antimicrobial Testing Leadership And Surveillance (ATLAS) program includes medical centers and microbiological labs located in five geographical regions (Europe, Asia-Pacific, South America, Africa-West Asia, and the United States). The isolates were collected from different specimens from patients who were hospitalized between 2012 and 2017 due to: 1) complicated skin and soft tissue infection; 2) complicated intra-abdominal infection; 3) complicated urinary tract infection; 4) lower respiratory tract infection; 5) bloodstream infection such as sepsis. All isolates were identified by each participating center, stored in tryptic soy broth with glycerol at −70°C, and shipped to International Health Management Associates, Inc. (IHMA; Schaumburg, IL, USA) for susceptibility testing. Only isolates considered to be the potential pathogen of the patient's infection were included in this study. Only the testing of the first isolate was performed per patient per infectious episode. Ethical approval was not required because the isolates were collected for routine diagnostic testing.

Antimicrobial Susceptibility Testing {#S0002-S2002}
------------------------------------

Antimicrobial susceptibility testing was performed by IHMA using the broth microdilution method. MICs were interpreted using both the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints.[@CIT0015],[@CIT0016] The breakpoint for ceftaroline is ≤1 μg/mL for CLSI and EUCAST. There is no breakpoint for oxacillin in the EUCAST file, leading to blank oxacillin results in the present study. The EUCAST file defined MIC \>2 μg/mL as MRSA, which is the same as MIC ≥4 μg/mL in the CLSI file, showing equivalence.

Comparator antimicrobial agents included those representing the most common classes of drugs used for the treatment of *S. aureus*. Ceftaroline and the following comparator agents were tested: clindamycin, daptomycin, erythromycin, gentamicin, levofloxacin, linezolid, minocycline, moxifloxacin, oxacillin, teicoplanin, tigecycline, trimethoprim-sulfamethoxazole (TMP-SMX), and vancomycin. The *S. aureus* ATCC 29213 quality control strain was concurrently tested.

Results {#S0003}
=======

Sample Retrieval {#S0003-S2001}
----------------

A total of 226 centers from five geographical regions (Europe, Asia-Pacific, South America, Africa-West Asia, and the United States) participated in the ATLAS program. The susceptibility testing of gentamicin and TMP-SMX was not performed in 2012 and 2013.

In Vitro Activity Of Ceftaroline Against *S. aureus* {#S0003-S2002}
----------------------------------------------------

During the study period, 61,045 isolates were tested, including 35,837 MRSA isolates (58.7%) and 25,208 MSSA isolates (41.3%) ([Table 1](#T0001){ref-type="table"}). For *S. aureus*, the MIC~50~, MIC~90~, and MIC range of ceftaroline were 0.5, 1, and 0.015--64 μg/mL, respectively. According to the CLSI and EUCAST MIC interpretations, the proportions of susceptible strains were both 93.7%, and the proportions of resistant strains were both 0.4%. For MRSA, the MIC~50~, MIC~90~, and MIC range of ceftaroline were 0.5, 2, and 0.015--64 μg/mL, respectively. According to the CLSI and EUCAST MIC interpretations, the proportions of susceptible strains were both 89.3%, and the proportions of resistant strains were both 0.7%. For MSSA, the MIC~50~, MIC~90~, and MIC range of ceftaroline were 0.25, 0.25, and 0.015--2 μg/mL, respectively. According to the CLSI and EUCAST MIC interpretations, the proportions of susceptible strains were both \>99.9%, and the proportions of resistant strains were both 0%.Table 1In Vitro Activity Of Ceftaroline Tested Against Isolates Of *Staphylococcus aureus*Organism(No. Of Isolates Tested)Ceftaroline MIC (mg/L)CLSI MIC InterpretationEUCAST MIC InterpretationMIC~50~MIC~90~MIC Range% Susceptible% SDD% Resistant% Susceptible% SDD% Resistant*S. aureus* (61,045)0.510.015--6493.75.90.493.75.90.4MRSA (35,837)0.520.015--6489.310.00.789.310.00.7MSSA (25,208)0.250.250.015--2\>99.9\<0.10\>99.9\<0.10[^1]

Susceptibilities Of *S. aureus* To Ceftaroline And Comparators From 2012 To 2017 {#S0003-S2003}
--------------------------------------------------------------------------------

The susceptibility of all *S. aureus*, MRSA, and MSSA strains to ceftaroline were 92.5--95.1%, 86.8--91.8%, and 99.9--100% from 2012 to 2017, respectively ([Table 2](#T0002){ref-type="table"}). In *S. aureus*, the susceptibility to all 14 tested antibiotics remained stable over time.Table 2Susceptibilities Of *Staphylococcus aureus* To Ceftaroline And Comparators From 2012 To 2017Variable% Susceptible To Antimicrobial Agents: CLSI/EUCAST (No. Of Isolates Tested)All Years201220132014201520162017*S. aureus* Ceftaroline93.7/93.7 (61,045)92.7/92.7 (8,827)92.5/92.5 (11,680)93.4/93.4 (11,191)93.9/93.9 (10,158)95.1/95.1 (10,682)94.7/94.7 (8,507) Clindamycin75.6/75.0 (61,045)73.8/73.0 (8,827)74.9/74.3 (11,680)74.4/74.1 (11,191)76.0/75.6 (10,158)75.8/75.0 (10,682)78.8/78.4 (8,507) Daptomycin99.8/99.8 (61,045)\>99.9/\>99.9 (8,827)99.4/99.4 (11,680)99.7/99.7 (11,191)99.8/99.8 (10,158)99.9/99.9 (10,682)99.9/99.9 (8,507) Erythromycin49.5/51.9 (61,045)42.3/48.4 (8,827)46.6/51.3 (11,680)50.1/51.7 (11,191)51.3/52.0 (10,158)50.7/51.3 (10,682)56.3/57/0 (8,507) Gentamicin85.3/61.8 (40,538)-/- (0)-/- (0)84.7/1.8 (11,191)85.4/84.9 (10,158)85.2/84.2 (10,682)85.9/85.2 (8,507) Levofloxacin57.8/57.8 (61,045)55.4/55.4 (8,827)57.1/57.1 (11,680)56.5/56.5 (11,191)58.6/58.6 (10,158)58.8/58.8 (10,682)60.5/60.5 (8,507) Linezolid\>99.9/\>99.9 (61,045)100/100 (8,827)\>99.9/\>99.9 (11,680)\>99.9/\>99.9 (11,191)100/100 (10,158)99.9/99.9 (10,682)\>99.9/\>99.9 (8,507) Minocycline93.6/89.9 (61,045)91.3/86.0 (8,827)93.0/86.4 (11,680)94.3/91.8 (11,191)94.4/91.8 (10,158)93.6/91.1 (10,682)95.2/92.6 (8,507) Moxifloxacin58.0/57.7 (61,045)55.9/55.1 (8,827)57.3/57.1 (11,680)56.8/56.5 (11,191)58.8/58.4 (10,158)58.9/58.6 (10,682)60.6/60.4 (8,507) Oxacilin41.3/- (61,045)40.5/- (8,827)42.9/- (11,680)40.7/- (11,191)39.8/- (10,158)40.4/- (10,682)43.6/- (8,507) Teicoplanin\>99.9/98.3 (61,045)\>99.9/98.8 (8,827)99.9/97.3 (11,680)\>99.9/98.6 (11,191)\>99.9/97.6 (10,158)100/98.7 (10,682)100/98.9 (8,507) Tigecycline99.0/99.0 (61,045)99.5/99.5 (8,827)97.8/97.8 (11,680)98.1/98.1 (11,191)99.7/99.7 (10,158)99.8/99.8 (10,682)99.6/99.6 (8,507) TMP-SMX96.7/96.7 (40,538)-/- (0)-/- (0)96.5/96.5 (11,191)96.9/96.9 (10,158)96.5/96.5 (10,682)96.8/96.8 (8,507) Vancomycin\>99.9/\>99.9 (61,045)100/100 (8,827)100/100 (11,680)\>99.9/\>99.9 (11,191)\>99.9/\>99.9 (10,158)100/100 (10,682)100/100 (8,507)MRSA Ceftaroline89.3/89.3 (35,837)87.7/87.7 (5,253)86.8/86.8 (6,666)89.0/89.0 (6,638)89.9/89.9 (6,112)91.8/91.8 (6,371)90.6/90.6 (4,797) Clindamycin61.7/61.1 (35,837)59.3/58.7 (5,253)59.8/59.3 (6,666)59.8/59.5 (6,638)63.4/62.9 (6,112)62.9/61.9 (6,371)65.7/65.1 (4,797) Daptomycin99.7/99.7 (35,837)99.9/99.9 (5,253)99.3/99.3 (6,666)99.7/99.7 (6,638)99.8/99.8 (6,112)\>99.9\>99.9 (6,371)99.8/99.8 (4,797) Erythromycin31.0/32.5 (35,837)23.8/27.2 (5,253)26.3/29.4 (6,666)30.6/31.8 (6,638)33.8/34.3 (6,112)33.2/33.7 (6,371)39.3/39.7 (4,797) Gentamicin78.4/56.6 (23,918)-/- (0)-/- (0)77.5/1.1 (6,638)78.8/78.3 (6,112)78.5/77.5 (6,371)79.0/78.0 (4,797) Levofloxacin32.9/32.9 (35,837)29.6/29.6 (5,253)29.9/29.9 (6,666)31.0/31.0 (6,638)35.5/35.5 (6,112)36.3/36.3 (6,371)35.8/35.8 (4,797) Linezolid\>99.9/\>99.9 (35,837)100/100 (5,253)\>99.9/\>99.9 (6,666)100/100 (6,638)100/100 (6,112)99.9/99.9 (6,371)\>99.9/\>99.9 (4,797) Minocycline89.9/85.0 (35,837)86.2/80.2 (5,253)88.5/79.9 (6,666)91.4/88.1 (6,638)91.2/87.4 (6,112)89.9/86.3 (6,371)92.5/88.5 (4,797) Moxifloxacin33.1/32.8 (35,837)29.9/29.3 (5,253)30.1/29.9 (6,666)31.4/31.0 (6,638)35.6/35.4 (6,112)36.4/36.1 (6,371)35.9/35.7 (4,797) Oxacilin0/- (35,837)0/- (5,253)0/- (6,666)0/- (6,638)0/- (6,112)0/- (6,371)0/- (4,797) Teicoplanin\>99.9/97.3 (35,837)99.9/98.1 (5,253)99.9/96.1 (6,666)\>99.9/97.8 (6,638)\>99.9/96.2 (6,112)100/98.0 (6,371)100/98.2 (4,797) Tigecycline98.7/98.7 (35,837)99.4/99.4 (5,253)96.8/96.8 (6,666)97.7/97.7 (6,638)99.5/99.5 (6,112)99.61/99.6 (6,371)99.3/99.3 (4,797) TMP-SMX95.5/95.5 (23,918)-/- (0)-/- (0)95.3/95.3 (6,638)95.7/95.7 (6,112)95.2/95.2 (6,371)95.8/95.8 (4,797) Vancomycin\>99.9/\>99.9 (35,837)100/100 (5,253)100/100 (6,666)\>99.9/\>99.9 (6,638)\>99.9/\>99.9 (6,112)100/100 (6,371)100/100 (4,797)MSSA Ceftaroline\>99.9/\>99.9 (25,208)99.9/99.9 (3,574)\>99.9/\>99.9 (5,014)99.9/99.9 (4,553)100/100 (4,046)100/100 (4,311)100/100 (3,710) Clindamycin95.3/94.7 (25,208)95.1/94.0 (3,574)95.0/94.3 (5,014)95.7/95.3 (4,553)95.1/94.7 (4,046)95.0/94.3 (4,311)95.8/95.7 (3,710) Daptomycin99.9/99.9 (25,208)100/100 (3,574)99.6/99.6 (5,014)99.8/99.8 (4,553)\>99.9/\>99.9 (4,046)99.9/99.9 (4,311)\>99.9/\>99.9 (3,710) Erythromycin75.8/79.4 (25,208)69.5/79.5 (3,574)73.5/80.4 (5,014)78.5/80.8 (4,553)77.7/78.6 (4,046)76.5/77.2 (4,311)78.4/79.4 (3,710) Gentamicin95.2/69.3 (16,620)-/- (0)-/- (0)95.3/2.6 (4,553)95.3/94.9 (4,046)95.2/94.2 (4,311)94.8/94.5 (3,710) Levofloxacin93.0/93.0 (25,208)93.3/93.3 (3,574)93.2/93.2 (5,014)93.7/93.7 (4,553)93.5/93.5 (4,046)92.1/92.1 (4,311)92.4/92.4 (3,710) Linezolid100/100 (25,208)100/100 (3,574)100/100 (5,014)\>99.9/\>99.9 (4,553)100/100 (4,046)100/100 (4,311)100/100 (3,710) Minocycline98.9/96.9 (25,208)98.8/94.6 (3,574)99.0/95.1 (5,014)98.7/97.2 (4,553)99.2/98.4 (4,046)99/98.4 (4,311)98.5/97.8 (3,710) Moxifloxacin93.3/92.9 (25,208)94.1/93.0 (3,574)93.4/93.2 (5,014)93.8/93.6 (4,553)93.7/93.3 (4,046)92.1/91.9 (4,311)92.5/92.4 (3,710) Oxacilin100/- (25,208)100/- (3,574)100/- (5,014)100/- (4,553)100/- (4,046)100/- (4,311)100/- (3,710) Teicoplanin\>99.9/99.6 (25,208)100/99.8 (3,574)\>99.9/98.8 (5,014)100/99.8 (4,553)100/99.8 (4,046)100/99.8 (4,311)100/99.8 (3,710) Tigecycline99.5/99.5 (25,208)99.6/99.6 (3,574)99.2/99.2 (5,014)98.7/98.7 (4,553)99.9/99.9 (4,046)100/100 (4,311)\>99.9/\>99.9 (3,710) TMP-SMX98.4/98.4 (16,620)-/- (0)-/- (0)98.3/98.3 (4,553)98.6/98.6 (4,046)98.5/98.5 (4,311)98.2/98.2 (3,710) Vancomycin100/100 (25,208)100/100 (3,574)100/100 (5,014)100/100 (4,553)100/100 (4,046)100/100 (4,311)100/100 (3,710)[^2]

The activities of daptomycin, linezolid, teicoplanin, tigecycline, TMP-SMX, and vancomycin against MRSA remained unchanged over the years. The activities of all other antimicrobial agents against MRSA, except for oxacillin, showed steady improvement during the 6-year period. Vancomycin (\>99.9% susceptible), linezolid (\>99.9% susceptible), teicoplanin (\>99.9% susceptible), daptomycin (99.7% susceptible), tigecycline (98.7% susceptible), and TMP-SMX (95.5% susceptible) were the effective agents (\>90% susceptible) against MRSA.

The activities of ceftaroline, clindamycin, daptomycin, gentamicin, linezolid, minocycline, oxacillin, teicoplanin, tigecycline, TMP-SMX, and vancomycin against MSSA were unchanged over the years. The activities of levofloxacin and moxifloxacin against MSSA slightly decreased over the years. Although the activity of erythromycin against MSSA showed steady improvement (69.5% to 78.4% susceptible) during the 6-year period, it was a suboptimal option considering the useful activities of all other antimicrobial agents (\>90% susceptible).

Susceptibilities Of *S. aureus* To Ceftaroline And Comparators In Different Regions {#S0003-S2004}
-----------------------------------------------------------------------------------

[Table 3](#T0003){ref-type="table"} shows that the susceptibility to ceftaroline of *S. aureus*, MRSA, and MSSA strains from the United States (99.7%, 99.5%, and 100%), Europe (96.6%, 94.0%, and \>99.9%), South America (91.3%, 84.4%, and 100%), and Africa/West Asia (95.7%, 92.3%, and 100%) was high, while the susceptibility of the strains from Asia-Pacific was markedly lower (85.0%, 75.9%, and 99.9%), especially for MRSA. In other words, the susceptibility of *S. aureus* and MRSA to ceftaroline was the highest in the United States, followed by Europe, Africa/West Asia, South America, and Asia-Pacific. Regarding MSSA, the susceptibility to ceftaroline was ≥99.9% in all regions of the world.Table 3Susceptibilities Of *Staphylococcus aureus* To Ceftaroline And Comparators In Different RegionsVariable% Susceptible To Antimicrobial Agents: CLSI/EUCAST (No. Of Isolates Tested)All RegionsThe United StatesEuropeAsia-PacificSouth AmericaAfrica-West Asia*S. aureus* Ceftaroline93.7/93.7 (61,045)99.7/99.7 (6,560)96.6/96.6 (28,462)85.0/85.0 (12,855)91.3/91.3 (8,471)95.7/95.7 (4,697) Clindamycin75.6/75.0 (61,045)78.0/77.7 (6,560)80.0/79.2 (28,462)65.0/64.6 (12,855)73.0/72.8 (8,471)78.5/78.0 (4,697) Daptomycin99.8/99.8 (61,045)99.9/99.9 (6,560)99.7/99.7 (28,462)99.8/99.8 (12,855)99.9/99.9 (8,471)99.9/99.9 (4,697) Erythromycin49.5/51.9 (61,045)25.9/28.1 (6,560)54.0/56.6 (28,462)47.0/49.1 (12,855)53.1/55.4 (8,471)55.4/57.7 (4,697) Gentamicin85.3/61.8 (40,538)97.1/60.4 (3,800)91.2/65.7 (19,188)69.3/55.2 (8,289)84.3/61.6 (6,022)79.0/57.6 (3,239) Levofloxacin57.8/57.8 (61,045)49.5/49.5 (6,560)54.7/54.7 (28,462)61.3/61.3 (12,855)69.8/69.8 (8,471)56.5/56.5 (4,697) Linezolid\>99.9/\>99.9 (61,045)\>99.9/\>99.9 (6,560)\>99.9/\>99.9 (28,462)\>99.9/\>99.9 (12,855)100/100 (8,471)\>99.9/\>99.9 (4,697) Minocycline93.6/89.9 (61,045)97.6/95.1 (6,560)95.9/92.7 (28,462)82.3/76.0 (12,855)99.4/98.0 (8,471)95.2/89.4 (4,697) Moxifloxacin58.0/57.7 (61,045)49.6/49.4 (6,560)54.9/54.5 (28,462)61.5/61.2 (12,855)70.1/69.8 (8,471)56.6/56.4 (4,697) Oxacilin41.3/- (61,045)32.4/- (6,560)43.5/- (28,462)37.9/- (12,855)44.5/- (8,471)44.1/- (4,697) Teicoplanin\>99.9/98.3 (61,045)100/99.6 (6,560)\>99.9/98.8 (28,462)\>99.9/95.8 (12,855)\>99.9/99.0 (8,471)\>99.9/99.1 (4,697) Tigecycline99.0/99.0 (61,045)99.7/99.7 (6,560)99.4/99.4 (28,462)96.9/96.9 (12,855)\>99.9/\>99.9 (8,471)99.9/99.9 (4,697) TMP-SMX96.7/96.7 (40,538)96.8/96.8 (3,800)98.3/98.3 (19,188)93.0/93.0 (8,289)99.0/99.0 (6,022)92.2/92.2 (3,239) Vancomycin\>99.9/\>99.9 (61,045)\>99.9/\>99.9 (6,560)\>99.9/\>99.9 (28,462)\>99.9/\>99.9 (12,855)100/100 (8,471)100/100 (4,697)MRSA Ceftaroline89.3/89.3 (35,837)99.5/99.5 (4,435)94.0/94.0 (16,087)75.9/75.9 (7,989)84.4/84.4 (4,700)92.3/92.3 (2,626) Clindamycin61.7/61.1 (35,837)70.3/70.1 (4,435)67.4/66.5 (16,087)49.6/49.2 (7,989)53.8/53.5 (4,700)62.8/62.4 (2,626) Daptomycin99.7/99.7 (35,837)99.9/99.9 (4,435)99.6/99.6 (16,087)99.8/99.8 (7,989)99.9/99.9 (4,700)99.9/99.9 (2,626) Erythromycin31.0/32.5 (35,837)10.9/11.9 (4,435)34.7/36.5 (16,087)29.8/31.3 (7,989)35.8/37.2 (4,700)36.8/38.0 (2,626) Gentamicin78.4/56.6 (23,918)96.4/59.9 (2,574)86.7/62.8 (11,021)56.8/45.6 (5,195)76.4/54.7 (3,290)68.3/49.0 (1,838) Levofloxacin32.9/32.9 (35,837)31.9/31.9 (4,435)25.0/25.0 (16,087)41.6/41.6 (7,989)48.5/48.5 (4,700)29.5/29.5 (2,626) Linezolid\>99.9/\>99.9 (35,837)\>99.9/\>99.9 (4,435)\>99.9/\>99.9 (16,087)\>99.9/\>99.9 (7,989)100/100 (4,700)\>99.9/\>99.9 (2,626) Minocycline89.9/85.0 (35,837)97.2/94.2 (4,435)93.5/89.4 (16,087)72.4/63.8 (7,989)99.3/98.1 (4,700)92.5/83.6 (2,626) Moxifloxacin33.1/32.8 (35,837)31.9/31.8 (4,435)25.2/24.9 (16,087)41.8/41.5 (7,989)48.7/48.4 (4,700)29.6/29.4 (2,626) Oxacilin0/- (35,837)0/- (4,435)0/- (16,087)0/- (7,989)0/- (4,700)0/- (2,626) Teicoplanin\>99.9/97.3 (35,837)100/99.4 (4,435)\>99.9/98.1 (16,087)99.9/93.4 (7,989)\>99.9/98.9 (4,700)100/98.6 (2,626) Tigecycline98.7/98.7 (35,837)99.5/99.5 (4,435)99.2/99.2 (16,087)95.8/95.8 (7,989)99.9/99.9 (4,700)99.9/99.9 (2,626) TMP-SMX95.5/95.5 (23,918)96.0/96.0 (2,574)97.7/97.7 (11,021)90.5/90.5 (5,195)98.7/98.7 (3,290)89.5/89.5 (1,838) Vancomycin\>99.9/\>99.9 (35,837)\>99.9/\>99.9 (4,435)\>99.9/\>99.9 (16,087)\>99.9/\>99.9 (7,989)100/100 (4,700)100/100 (2,626)MSSA Ceftaroline\>99.9/\>99.9 (25,208)100/100 (2,125)\>99.9/\>99.9 (12,375)99.9/99.9 (4,866)100/100 (3,771)100/100 (2,071) Clindamycin95.3/94.7 (25,208)94.0/93.7 (2,125)96.4/95.7 (12,375)90.3/89.8 (4,866)97.0/96.7 (3,771)98.4/97.7 (2,071) Daptomycin99.9/99.9 (25,208)99.8/99.8 (2,125)99.8/99.8 (12,375)99.9/99.9 (4,866)\>99.9/\>99.9 (3,771)100/100 (2,071) Erythromycin75.8/79.4 (25,208)57.1/61.9 (2,125)79.0/82.6 (12,375)75.2/78.3 (4,866)74.6/78.2 (3,771)79.0/82.6 (2,071) Gentamicin95.2/69.3 (16,620)98.7/61.5 (1,226)97.3/69.7 (8,167)90.3/71.3 (3,094)93.8/69.9 (2,732)93.2/68.9 (1,401) Levofloxacin93.0/93.0 (25,208)86.3/86.3 (2,125)93.3/93.3 (12,375)93.7/93.7 (4,866)96.5/96.5 (3,771)90.8/90.8 (2,071) Linezolid100/100 (25,208)100/100 (2,125)100/100 (12,375)\>99.9/\>99.9 (4,866)100/100 (3,771)100/100 (2,071) Minocycline98.9/96.9 (25,208)98.4/97.0 (2,125)98.9/96.9 (12,375)98.7/96.1 (4,866)99.5/98.0 (3,771)98.6/96.7 (2,071) Moxifloxacin93.3/92.9 (25,208)86.5/86.3 (2,125)93.6/93.1 (12,375)93.9/93.6 (4,866)96.7/96.4 (3,771)90.9/90.6 (2,071) Oxacilin100/- (25,208)100/- (2,125)100/- (12,375)100/- (4,866)100/- (3,771)100/- (2,071) Teicoplanin\>99.9/99.6 (25,208)100/\>99.9 (2,125)\>99.9/99.7 (12,375)100/99.6 (4,866)100/99.1 (3,771)\>99.9/99.7 (2,071) Tigecycline99.5/99.5 (25,208)99.9/99.9 (2,125)99.6/99.6 (12,375)98.7/98.7 (4,866)\>99.9/\>99.9 (3,771)\>99.9/\>99.9 (2,071) TMP-SMX98.4/98.4 (16,620)98.6/98.6 (1,226)99.0/99.0 (8,167)97.1/97.1 (3,094)99.3/99.3 (2,732)95.9/95.9 (1,401) Vancomycin100/100 (25,208)100/100 (2,125)100/100 (12,375)100/100 (4,866)100/100 (3,771)100/100 (2,071)[^3]

When examining the susceptibility of MRSA to comparator agents, the susceptibility among the five geographic regions was comparable and remarkable for vancomycin (\>99.9--100%), linezolid (\>99.9--100%), teicoplanin (99.9--100%), and daptomycin (99.6--99.9%). The activity of tigecycline against MRSA was favorable but relatively low in Asia-Pacific (95.8% susceptible), compared with other regions (99.2--99.9% susceptible). Minocycline and TMP-SMX were effective (\>90% susceptible) against MRSA in all regions, except for Asia-Pacific with minocycline (72.4% susceptible) and Africa-West Asia with TMP-SMX (89.5% susceptible). The activities of daptomycin, linezolid, minocycline, oxacillin, teicoplanin, tigecycline, and vancomycin against MSSA showed similar trends with ceftaroline. Levofloxacin and moxifloxacin had relatively poor activity in the United States (86.3% and 86.5% susceptible, respectively), compared with other regions (\>90% susceptible). Erythromycin was not an optimal option in any region.

Characteristics Of Ceftaroline-Resistant *S. aureus* {#S0003-S2005}
----------------------------------------------------

[Table 4](#T0004){ref-type="table"} shows the distribution of ceftaroline MICs for isolates of ceftaroline-resistant *S. aureus*. These isolates were all MRSA. The MIC~50~, MIC~90~, and MIC range of ceftaroline were 4, 4, and 4--64 μg/mL, respectively. [Table 5](#T0005){ref-type="table"} shows the susceptibility/resistance pattern of these strains against the comparators. The susceptibility of ceftaroline-resistant MRSA against clindamycin, erythromycin, gentamicin, levofloxacin, and moxifloxacin was dramatically lower than overall MRSA.Table 4Distribution Of Ceftaroline MICs For Isolates Of Ceftaroline-Resistant *Staphylococcus aureus*Organism (No. Of Isolates Tested)No. Of Isolates Inhibited At Ceftaroline MIC (mg/L)MIC (mg/L)48163264MIC~50~MIC~90~MRSA\* (263)2382200344[^4][^5] Table 5Susceptibilities Of Ceftaroline-Resistant MRSA To ComparatorsAntimicrobial Agent (No. Of Isolates Tested)CLSI MIC InterpretationEUCAST MIC Interpretation% Susceptible% Intermediate% Resistant% Susceptible% Intermediate% ResistantClindamycin (263)8.00.491.68.0092.0Daptomycin (263)98.91.1098.901.1Erythromycin (263)1.11.997.01.90.497.7Gentamicin (182)9.30.690.18.8091.2Levofloxacin (263)0010000100Linezolid (263)1000010000Minocycline (263)76.49.514.170.31.927.8Moxifloxacin (263)0010000100Oxacilin (263)00100------Teicoplanin (263)1000090.109.9Tigecycline (263)94.35.7094.305.7TMP-SMX (182)96.703.396.71.12.2Vancomycin (263)1000010000[^6]

Discussion {#S0004}
==========

There is a plea for worldwide, automated, and comprehensive surveillance of antimicrobial resistance patterns.[@CIT0017] The ATLAS program provides the comprehensive susceptibility profile of ceftaroline and other antimicrobial agents against *S. aureus*. It involves data from different years and regions of the world and helps provide certain help for global surveillance of bacterial resistance. The ATLAS program also includes other Gram-positive or -negative bacteria, but this study only focused on *S. aureus*, which is of greater clinical attention to the important threat level of MRSA. The resistance of other pathogenic bacteria will be analyzed in future studies.

During the study period and across the five geographical regions covered by ATLAS, MRSA represented 58.7% of *S. aureus* isolates. This rate is higher than that of the Tigecycline Evaluation and Surveillance Trial (TEST) (40.2%)[@CIT0018] and TEST study specific to blood-borne infections (33.0%).[@CIT0019] The SENTRY surveillance report for Asia-Pacific and Latin America showed MRSA rates of 37.0% and 44.7%, respectively,[@CIT0020],[@CIT0021] which are lower than in the ATLAS study. These differences might come from the time period covered by the different studies, as well as from the source of patients/samples. In the present study, the frequencies of MRSA across the years were 59.5% in 2012, 57.1% in 2013, 59.3% in 2014, 60.2% in 2015, 59.6% in 2016, and 56.4% in 2017, suggesting a relatively stable frequency during this period.

Previous studies reported that the lowest antibiotic susceptibility of blood-borne infections from *S. aureus* was to penicillin (around 15%).[@CIT0018],[@CIT0019] A surveillance study from the Antimicrobial Resistance Surveillance Network in Germany reported that the susceptibility of MRSA to linezolid, teicoplanin, tigecycline, and vancomycin was high.[@CIT0022] The SENTRY program indicates that the susceptibility of MRSA to vancomycin remains high around the globe and that newer agents also show good susceptibility profiles.[@CIT0023] The report from the German surveillance network did not examine ceftaroline,[@CIT0022] but the SENTRY program reported that the susceptibility of MSSA to ceftaroline was 100% and that of MRSA was 91.6%.[@CIT0023] For skin and soft tissue infections with suspected MRSA, the guidelines usually recommend oral TMP-SMX, doxycycline, minocycline, and clindamycin, as well as newer agents like linezolid and tedizolid; intravenous vancomycin is the first choice for hospitalized patients, followed by daptomycin when vancomycin cannot be given.[@CIT0001],[@CIT0024]--[@CIT0026] For bacteremia of suspected MRSA origin, vancomycin and daptomycin are the first choices, followed by ceftaroline combination regimens and teicoplanin.[@CIT0001],[@CIT0027],[@CIT0028] Ceftaroline is a rapid-acting agent and is a treatment option for *S. aureus* infection, especially for MRSA.[@CIT0029] The present study showed that both MRSA and MSSA are susceptible to ceftaroline. The present study revealed that the susceptibility of MRSA to ceftaroline was higher than for clindamycin and similar to that of minocycline. On the other hand, susceptibility of MRSA to daptomycin, vancomycin, TMP-SMX, and linezolid was higher than that of ceftaroline. Therefore, daptomycin, vancomycin, TMP-SMX, and linezolid should not be used empirically in the presence of infections in general, but should be kept as empiric therapy for critical cases who cannot afford the time to fail to a first line of therapy, or kept as definitive treatment for patients who fail to other antibiotics. The other antibiotics recommended by the guidelines were not tested in the present study. Regarding MSSA, the susceptibility to the 14 agents studied here was high.

Of note, of the ceftaroline-resistant strains (263/61,045, 0.4%), most (242/263, 92.0%) were from Asia, including Thailand (168 strains), China (35 strains), and Korea (35 strains). As ceftaroline was not approved in these countries between 2012 and 2017, we consider that these ceftaroline-resistant strains were naturally circulant strains. These isolates were all MRSA. The results also show that the susceptibility/resistance pattern of these ceftaroline-resistant MRSA strains was different than that of overall MRSA. The susceptibility of ceftaroline-resistant MRSA against clindamycin, erythromycin, gentamicin, levofloxacin, and moxifloxacin was dramatically lower than overall MRSA.

The results showed that the resistance of MRSA to ceftaroline, clindamycin, gentamicin, and minocycline in the Asia-Pacific region was much higher than in the rest of the world. A report from the World Health Organization highlighted that antibiotic resistance has increased all over the world, but that the increase was particularly alarming in Asia because of antibiotic over-prescription, poor infection control, poor waste management, overuse of antibiotics in farming, food security, and restricted access to the newest antibiotics,[@CIT0030] as supported by a number of studies.[@CIT0031],[@CIT0032] Asia-Pacific is the most populous region of the world, but many of its countries are among the poorest per capita, leading to poor health infrastructure.[@CIT0033] The rates of resistance of *S. aureus* to oxacillin (82.1%), ciprofloxacin (78.2%), clindamycin (64.2%), erythromycin (76.5%), and tetracycline (70.9%) are high in Asian countries.[@CIT0034] MRSA significantly affects the outcomes of Asian patients with *S. aureus* infection.[@CIT0035] The TEST study showed that Africa and Asia were the two regions of the world with the highest occurrence of *S. aureus* resistant to multiple antibiotics among blood-borne infections.[@CIT0019]

A surveillance study from the Antimicrobial Resistance Surveillance Network in Germany reported that the resistance pattern for tobramycin, ciprofloxacin, moxifloxacin, clindamycin, erythromycin, tetracyclines, and gentamicin evolved from 2010 to 2015.[@CIT0022] In the present study, when considering all five regions together, the susceptibility to ceftaroline showed a rising tendency from 2012 to 2017, while the susceptibility to daptomycin, linezolid, teicoplanin, tigecycline, TMP-SMX, and vancomycin remained stable.

Conclusions {#S0005}
===========

The present study examined the susceptibility of *S. aureus* to ceftaroline and comparator antimicrobial agents in patients hospitalized due to infection. For MRSA, the MIC~50~, MIC~90~, and MIC range of ceftaroline were higher than for MSSA. The susceptibility of *S. aureus*, MRSA, and MSSA strains to ceftaroline from the United States, Europe, South America, and Africa/West Asia is high, while the susceptibility of the strains from Asia-Pacific is markedly lower, especially for MRSA.
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[^1]: **Abbreviations:** MIC, minimal inhibitory concentration; CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; SDD, susceptible-dose dependent; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-sensitive *Staphylococcus aureus*.

[^2]: **Abbreviations:** CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; TMP-SMX, trimethoprim-sulfamethoxazole; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-sensitive *Staphylococcus aureus*.

[^3]: **Abbreviations:** CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; TMP-SMX, trimethoprim-sulfamethoxazole; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-sensitive *Staphylococcus aureus*.

[^4]: **Note:** \*All ceftaroline-resistant isolates were MRSA.

[^5]: **Abbreviations:** MIC, minimal inhibitory concentration; MRSA, methicillin-resistant *Staphylococcus aureus*.

[^6]: **Abbreviations:** MRSA, methicillin-resistant *Staphylococcus aureus*; CLSI, Clinical and Laboratory Standards Institute; MIC, minimal inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing; TMP-SMX, trimethoprim sulfamethoxazole.
